- Details
- Eric Small presents a discussion on primary small cell prostate cancer and therapeutic approaches to consider in aggressive variant prostate cancer (AVPC) and small cell neuroendocrine prostate cancer (t-SCNC) patients. Biographies: Eric Small, MD, Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF, Pro...
|
- Details
- Mark Rubin joins Alicia Morgans to discuss emerging therapies and emerging therapeutic targets in prostate cancer. Topics covered include types of resistance, epigenetic therapies, and EZH2 inhibitors. Dr. Rubin also shares his thoughts on how he sees molecular pathology impacting cancer care in the next decade. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director of Dep...
|
- Details
- Rob Reiter and Alicia Morgans discuss the use of MRI and active surveillance in prostate cancer treatment. Dr. Reiter explains how MRI is used to improve proper patient selection for active surveillance. He also discusses how he was an early adopter of MRI and how he incorporates an MRI-guided biopsy program in his practice. In conclusion, Dr. Reiter and Dr. Morgans agree it’s important to note th...
|
- Details
- In a conversation with Alicia Morgans, Professor Bertrand Tombal provides a synopsis of metastatic subtypes in the ARASENS trial outcomes. The ARASENS trial investigated the benefit of darolutamide by comparing ADT plus docetaxel and darolutamide versus a placebo group. Tombal and Morgans wrap up the conversation by acknowledging the pragmatic and effective treatment recommendations that resulted...
|
- Details
- Alexandra Sokolova joins Alicia Morgans to discuss her work on biochemical recurrent prostate cancer. Dr. Sokolova and her team at OHSU hypothesize that a combination of durvalumab and olaparib will result in a deeper remission, delay the need for ADT, and improve the quality of life for patients who have a shorter PSA doubling time and a higher risk of developing metastasis. Biographies: Alexandr...
|
- Details
- Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well as t...
|
- Details
- Stephen Freedland presents the manuscript entitled A Phase 3 Randomized Study of Enzalutamide Plus Leuprolide and Enzalutamide Monotherapy in High-Risk Nonmetastatic Hormone-Sensitive Prostate Cancer with Rising PSA After Local Therapy: EMBARK Study Design. The objective of EMBARK was to value the efficacy and safety of enzalutamide in combination with leuprolide acetate or monotherapy compared wi...
|
- Details
- The Scientific Director at the Society of Oncology and Hematology from del Cesar, Columbia, Ray Manneh Kopp joins Phillip Koo bringing a global perspective to a discussion on the novel approaches in the management of high-risk prostate cancer. They discuss the diagnosis criteria currently being used, the novelties in the diagnosis, and adjuvant alternatives in this disease. Biographies: Ray Manneh...
|
- Details
- Men who undergo surgery as definitive therapy for their localized prostate cancer generally only receive subsequent radiation therapy if their surgical pathology shows high-risk adverse pathologic features (adjuvant radiotherapy) or if they experience biochemical recurrence (salvage radiotherapy). Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/A...
|
- Details
- Samir Taneja joins a panel of urologists to debate the use of ultrasound when compared to magnetic resonance imaging (MRI) as the best diagnostic and guidance imaging option for prostate cancer patients. Prostate ultrasound, specifically, micro-ultrasound, has a high sensitivity for predicting clinically significant cancer however its diagnostic accuracy is dependent on the urologist performing th...
|
